These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37045991)
21. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Dai Y; Zhang L; Yu J; Zhou X; He H; Ji Y; Wang K; Du X; Liu X; Tang Y; Deng S; Langley C; Li WG; Zhang J; Feng J; Sahakian BJ; Luo Q; Li F Sci Bull (Beijing); 2021 Aug; 66(15):1591-1598. PubMed ID: 36654288 [TBL] [Abstract][Full Text] [Related]
22. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Frye RE; Slattery J; Delhey L; Furgerson B; Strickland T; Tippett M; Sailey A; Wynne R; Rose S; Melnyk S; Jill James S; Sequeira JM; Quadros EV Mol Psychiatry; 2018 Feb; 23(2):247-256. PubMed ID: 27752075 [TBL] [Abstract][Full Text] [Related]
23. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Veenstra-VanderWeele J; Cook EH; King BH; Zarevics P; Cherubini M; Walton-Bowen K; Bear MF; Wang PP; Carpenter RL Neuropsychopharmacology; 2017 Jun; 42(7):1390-1398. PubMed ID: 27748740 [TBL] [Abstract][Full Text] [Related]
24. Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. Klaiman C; Huffman L; Masaki L; Elliott GR J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):320-8. PubMed ID: 23782126 [TBL] [Abstract][Full Text] [Related]
25. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596 [TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Zimmerman AW; Singh K; Connors SL; Liu H; Panjwani AA; Lee LC; Diggins E; Foley A; Melnyk S; Singh IN; James SJ; Frye RE; Fahey JW Mol Autism; 2021 May; 12(1):38. PubMed ID: 34034808 [TBL] [Abstract][Full Text] [Related]
27. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Carminati GG; Gerber F; Darbellay B; Kosel MM; Deriaz N; Chabert J; Fathi M; Bertschy G; Ferrero F; Carminati F Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():85-95. PubMed ID: 26361994 [TBL] [Abstract][Full Text] [Related]
28. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C; CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433 [TBL] [Abstract][Full Text] [Related]
30. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism. Hendren RL; James SJ; Widjaja F; Lawton B; Rosenblatt A; Bent S J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):774-783. PubMed ID: 26889605 [TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
32. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial. Lee SH; Shin S; Kim TH; Kim SM; Do TY; Park S; Lee B; Shin HJ; Lee J; Lee JY; Chang GT Trials; 2019 Jul; 20(1):434. PubMed ID: 31307524 [TBL] [Abstract][Full Text] [Related]
33. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder. Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058 [TBL] [Abstract][Full Text] [Related]
34. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Guastella AJ; Gray KM; Rinehart NJ; Alvares GA; Tonge BJ; Hickie IB; Keating CM; Cacciotti-Saija C; Einfeld SL J Child Psychol Psychiatry; 2015 Apr; 56(4):444-52. PubMed ID: 25087908 [TBL] [Abstract][Full Text] [Related]
35. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. Momtazmanesh S; Amirimoghaddam-Yazdi Z; Moghaddam HS; Mohammadi MR; Akhondzadeh S Psychiatry Clin Neurosci; 2020 Jul; 74(7):398-405. PubMed ID: 32347624 [TBL] [Abstract][Full Text] [Related]
36. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. Masi A; Lampit A; Glozier N; Hickie IB; Guastella AJ Transl Psychiatry; 2015 Sep; 5(9):e640. PubMed ID: 26393486 [TBL] [Abstract][Full Text] [Related]
37. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123 [TBL] [Abstract][Full Text] [Related]
38. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. Hendouei F; Sanjari Moghaddam H; Mohammadi MR; Taslimi N; Rezaei F; Akhondzadeh S J Clin Pharm Ther; 2020 Apr; 45(2):324-334. PubMed ID: 31714621 [TBL] [Abstract][Full Text] [Related]
39. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. Dawson G; Sun JM; Baker J; Carpenter K; Compton S; Deaver M; Franz L; Heilbron N; Herold B; Horrigan J; Howard J; Kosinski A; Major S; Murias M; Page K; Prasad VK; Sabatos-DeVito M; Sanfilippo F; Sikich L; Simmons R; Song A; Vermeer S; Waters-Pick B; Troy J; Kurtzberg J J Pediatr; 2020 Jul; 222():164-173.e5. PubMed ID: 32444220 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial. Ou J; Smith RC; Tobe RH; Lin J; Arriaza J; Fahey JW; Liu R; Zeng Y; Liu Y; Huang L; Shen Y; Li Y; Cheng D; Cornblatt B; Davis JM; Zhao J; Wu R; Jin H J Autism Dev Disord; 2024 Feb; 54(2):628-641. PubMed ID: 36427174 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]